VALACYCLOVIR
13 general benefit · 8 not a benefit
Other products in the same Health Canada class (J05A, J05AB) — coverage varies; not interchangeable
- Acyclovir (Zovirax): general benefit, Not a benefit
- Ganciclovir (Cytovene): general benefit
- Famciclovir (Famvir): limited Use 147, Not a benefit
- Remdesivir (Veklury): limited Use 722
- Valganciclovir (Valcyte): limited Use 374, 568, 569, Limited Use 571, 572, 573
- Abacavir + lamivudine + zidovudine (Trizivir): general benefit
48 more in the class list below
Apo-Valacyclovir · DIN 02295822 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Valacyclovir · DIN 02295822
Manufacturer: Apotex Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-05-23 · brand APO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Apotex inc · schedule Prescription
Apo-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78118 · Verify on the e-Formulary ↗ (DIN 02295822)
Source record
DIN 02295822: Apo-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295822
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78118
Interchangeable products
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: shortage reported ended 2026-07-23 (report last updated 2026-07-23); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295822
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valacyclovir · DIN 02405040 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valacyclovir · DIN 02405040
Manufacturer: Auro Pharma Inc.; listing date 2013-07-30
Health Canada: Marketed since 2015-07-24 · brand AURO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Auro pharma inc · schedule Prescription
Auro-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88988 · Verify on the e-Formulary ↗ (DIN 02405040)
Source record
DIN 02405040: Auro-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id AUR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405040
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88988
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2024-08-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405040
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Valacyclovir · DIN 02440598 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Valacyclovir · DIN 02440598
Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30
Health Canada: Marketed since 2021-04-13 · brand JAMP VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Jamp pharma corporation · schedule Prescription
Jamp Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92496 · Verify on the e-Formulary ↗ (DIN 02440598)
Source record
DIN 02440598: Jamp Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02440598
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92496
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02440598
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Valacyclovir · DIN 02351579 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mylan-Valacyclovir · DIN 02351579
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2010-07-20
Health Canada: Marketed since 2010-05-25 · brand MYLAN-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83683 · Verify on the e-Formulary ↗ (DIN 02351579)
Source record
DIN 02351579: Mylan-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id MYL
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351579
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83683
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: active shortage (reported 2026-08-28, estimated to end 2027-01-12, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351579
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Valacyclovir · DIN 02298457 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Valacyclovir · DIN 02298457
Manufacturer: Pharmascience Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-05-16 · brand PMS-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Pharmascience inc · schedule Prescription
PMS-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78376 · Verify on the e-Formulary ↗ (DIN 02298457)
Source record
DIN 02298457: PMS-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id PMS
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298457
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78376
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2024-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298457
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Valacyclovir · DIN 02316447 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Riva-Valacyclovir · DIN 02316447
Manufacturer: Laboratoire Riva Inc.; listing date 2025-08-29
Health Canada: Marketed since 2008-10-27 · brand RIVA-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Laboratoire riva inc. · schedule Prescription
Riva-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80195 · Verify on the e-Formulary ↗ (DIN 02316447)
Source record
DIN 02316447: Riva-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id RIA
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316447
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80195
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2025-01-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02316447
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valacyclovir · DIN 02347091 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valacyclovir · DIN 02347091
Manufacturer: Sandoz Canada Inc.; listing date 2015-09-30
Health Canada: Marketed since 2015-07-21 · brand SANDOZ VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE MONOHYDRATE) 500 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83249 · Verify on the e-Formulary ↗ (DIN 02347091)
Source record
DIN 02347091: Sandoz Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id SDZ
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02347091
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83249
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2025-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02347091
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valacyclovir · DIN 02357534 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Valacyclovir · DIN 02357534
Manufacturer: Teva Canada Limited; listing date 2012-11-27
Health Canada: Marketed since 2012-11-01 · brand TEVA-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Teva canada limited · schedule Prescription
Teva-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84264 · Verify on the e-Formulary ↗ (DIN 02357534)
Source record
DIN 02357534: Teva-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id TEV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357534
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84264
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357534
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valacyclovir · DIN 02442000 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valacyclovir · DIN 02442000
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28
Health Canada: Marketed since 2018-05-04 · brand VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92637 · Verify on the e-Formulary ↗ (DIN 02442000)
Source record
DIN 02442000: Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id SIV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442000
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92637
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2020-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442000
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valacyclovir · DIN 02454645 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valacyclovir · DIN 02454645
Manufacturer: Sanis Health Inc.; listing date 2016-11-30
Health Canada: Marketed since 2016-06-10 · brand VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Sanis health inc · schedule Prescription
Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94135 · Verify on the e-Formulary ↗ (DIN 02454645)
Source record
DIN 02454645: Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id SAI
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454645
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94135
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended 2024-11-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454645
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valtrex · DIN 02219492 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Valtrex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists VALTREX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, Sep 10, 2026 ↗)1 brand, same coverage
Valtrex · DIN 02219492
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-12-19
Health Canada: Marketed since 2002-09-27 · brand VALTREX · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Glaxosmithkline inc · schedule Prescription
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20218 · Verify on the e-Formulary ↗ (DIN 02219492)
Source record
DIN 02219492: Valtrex
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id GSK
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $4.6513; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02219492
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20218
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Shortage status: resolved shortage (ended 2026-04-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02219492
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Valacyclovir · DIN 02354705 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Valacyclovir · DIN 02354705
Manufacturer: Apotex Inc.; listing date 2010-10-28
Health Canada: Marketed since 2011-10-21 · brand APO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83987 · Verify on the e-Formulary ↗ (DIN 02354705)
Source record
DIN 02354705: Apo-Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id APX
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354705
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83987
Interchangeable products
Auro-Valacyclovir · DIN 02405059 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: resolved shortage (ended 2025-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02354705
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valacyclovir · DIN 02405059 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Valacyclovir · DIN 02405059
Manufacturer: Auro Pharma Inc.; listing date 2020-12-18
Health Canada: Marketed since 2021-01-09 · brand AURO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Auro pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88989 · Verify on the e-Formulary ↗ (DIN 02405059)
Source record
DIN 02405059: Auro-Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id AUR
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405059
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88989
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: resolved shortage (ended 2024-12-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405059
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Valacyclovir · DIN 02558858 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Valacyclovir · DIN 02558858
Manufacturer: Jamp Pharma Corporation; listing date 2026-02-27
Health Canada: Marketed since 2025-12-10 · brand JAMP VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106206 · Verify on the e-Formulary ↗ (DIN 02558858)
Source record
DIN 02558858: Jamp Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id JPC
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02558858
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106206
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Auro-Valacyclovir · DIN 02405059 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02558858
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Valacyclovir · DIN 02351560 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Valacyclovir · DIN 02351560
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2010-07-20
Health Canada: Marketed since 2010-05-25 · brand MYLAN-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83684 · Verify on the e-Formulary ↗ (DIN 02351560)
Source record
DIN 02351560: Mylan-Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id MYL
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351560
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83684
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Auro-Valacyclovir · DIN 02405059 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: active shortage (reported 2025-12-20, estimated to end 2027-01-12, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351560
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Valacyclovir · DIN 02381230 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Valacyclovir · DIN 02381230
Manufacturer: Pharmascience Inc.; listing date 2012-05-29
Health Canada: Marketed since 2012-03-13 · brand PMS-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86701 · Verify on the e-Formulary ↗ (DIN 02381230)
Source record
DIN 02381230: PMS-Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id PMS
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381230
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86701
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Auro-Valacyclovir · DIN 02405059 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: resolved shortage (ended 2024-11-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381230
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valacyclovir · DIN 02519585 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valacyclovir · DIN 02519585
Manufacturer: Sanis Health Inc.; listing date 2021-12-17
Health Canada: Marketed since 2022-05-23 · brand VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100883 · Verify on the e-Formulary ↗ (DIN 02519585)
Source record
DIN 02519585: Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id SAI
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519585
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100883
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Auro-Valacyclovir · DIN 02405059 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: resolved shortage (ended 2024-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519585
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valacyclovir · DIN 02553511 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valacyclovir · DIN 02553511
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30
Health Canada: Marketed since 2025-11-27 · brand VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104244 · Verify on the e-Formulary ↗ (DIN 02553511)
Source record
DIN 02553511: Valacyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id SIV
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $5.8537; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553511
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104244
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Auro-Valacyclovir · DIN 02405059 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valtrex · DIN 02246559 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553511
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valtrex · DIN 02246559 · 1000mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Valtrex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists VALTREX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, Sep 10, 2026 ↗)1 brand, same coverage
Valtrex · DIN 02246559
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2010-07-20
Health Canada: Marketed since 2005-05-09 · brand VALTREX · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000 MG · company Glaxosmithkline inc · schedule Prescription
Valtrex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70742 · Verify on the e-Formulary ↗ (DIN 02246559)
Source record
DIN 02246559: Valtrex
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800339; group id 114; item number 0197; lccId None; manufacturer id GSK
Source form: Tab; strength: 1000mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246559
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70742
Interchangeable products
Apo-Valacyclovir · DIN 02354705 · not recorded
Auro-Valacyclovir · DIN 02405059 · not recorded
Jamp Valacyclovir · DIN 02558858 · not recorded
Mylan-Valacyclovir · DIN 02351560 · not recorded
PMS-Valacyclovir · DIN 02381230 · not recorded
Valacyclovir · DIN 02519585 · not recorded
Valacyclovir · DIN 02553511 · not recorded
Shortage status: resolved shortage (ended 2026-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246559
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Co Valacyclovir · DIN 02331748 · 500mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-12 — choose a marketed DIN from the same-category list.Discontinued 2018-11-12 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-11-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Valacyclovir · DIN 02331748
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2010-10-28
Health Canada: Cancelled post market since 2018-11-12 · brand CO VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Cobalt pharmaceuticals company · schedule Prescription
Co Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81743 · Verify on the e-Formulary ↗ (DIN 02331748)
Source record
DIN 02331748: Co Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id COB
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02331748
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81743
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02331748
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-11-12 — choose a marketed DIN from the same-category list.
Jamp-Valacyclovir · DIN 02441454 · 500mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-25 — choose a marketed DIN from the same-category list.Discontinued 2024-11-25 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-25 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-11-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Valacyclovir · DIN 02441454
Manufacturer: Jamp Pharma Corporation; listing date 2015-12-22
Health Canada: Cancelled post market since 2024-11-25 · brand JAMP-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Valacyclovir: Formulary list price $0.6198/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92583 · Verify on the e-Formulary ↗ (DIN 02441454)
Source record
DIN 02441454: Jamp-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441454
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92583
Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: active shortage (reported 2019-11-01, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441454
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-11-25 — choose a marketed DIN from the same-category list.